Cargando…
NAD(+) metabolism-based immunoregulation and therapeutic potential
Nicotinamide adenine dinucleotide (NAD(+)) is a critical metabolite that acts as a cofactor in energy metabolism, and serves as a cosubstrate for non-redox NAD(+)-dependent enzymes, including sirtuins, CD38 and poly(ADP-ribose) polymerases. NAD(+) metabolism can regulate functionality attributes of...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171153/ https://www.ncbi.nlm.nih.gov/pubmed/37165408 http://dx.doi.org/10.1186/s13578-023-01031-5 |
_version_ | 1785039368064335872 |
---|---|
author | Fang, Jiankai Chen, Wangwang Hou, Pengbo Liu, Zhanhong Zuo, Muqiu Liu, Shisong Feng, Chao Han, Yuyi Li, Peishan Shi, Yufang Shao, Changshun |
author_facet | Fang, Jiankai Chen, Wangwang Hou, Pengbo Liu, Zhanhong Zuo, Muqiu Liu, Shisong Feng, Chao Han, Yuyi Li, Peishan Shi, Yufang Shao, Changshun |
author_sort | Fang, Jiankai |
collection | PubMed |
description | Nicotinamide adenine dinucleotide (NAD(+)) is a critical metabolite that acts as a cofactor in energy metabolism, and serves as a cosubstrate for non-redox NAD(+)-dependent enzymes, including sirtuins, CD38 and poly(ADP-ribose) polymerases. NAD(+) metabolism can regulate functionality attributes of innate and adaptive immune cells and contribute to inflammatory responses. Thus, the manipulation of NAD(+) bioavailability can reshape the courses of immunological diseases. Here, we review the basics of NAD(+) biochemistry and its roles in the immune response, and discuss current challenges and the future translational potential of NAD(+) research in the development of therapeutics for inflammatory diseases, such as COVID-19. |
format | Online Article Text |
id | pubmed-10171153 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101711532023-05-11 NAD(+) metabolism-based immunoregulation and therapeutic potential Fang, Jiankai Chen, Wangwang Hou, Pengbo Liu, Zhanhong Zuo, Muqiu Liu, Shisong Feng, Chao Han, Yuyi Li, Peishan Shi, Yufang Shao, Changshun Cell Biosci Review Nicotinamide adenine dinucleotide (NAD(+)) is a critical metabolite that acts as a cofactor in energy metabolism, and serves as a cosubstrate for non-redox NAD(+)-dependent enzymes, including sirtuins, CD38 and poly(ADP-ribose) polymerases. NAD(+) metabolism can regulate functionality attributes of innate and adaptive immune cells and contribute to inflammatory responses. Thus, the manipulation of NAD(+) bioavailability can reshape the courses of immunological diseases. Here, we review the basics of NAD(+) biochemistry and its roles in the immune response, and discuss current challenges and the future translational potential of NAD(+) research in the development of therapeutics for inflammatory diseases, such as COVID-19. BioMed Central 2023-05-10 /pmc/articles/PMC10171153/ /pubmed/37165408 http://dx.doi.org/10.1186/s13578-023-01031-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Fang, Jiankai Chen, Wangwang Hou, Pengbo Liu, Zhanhong Zuo, Muqiu Liu, Shisong Feng, Chao Han, Yuyi Li, Peishan Shi, Yufang Shao, Changshun NAD(+) metabolism-based immunoregulation and therapeutic potential |
title | NAD(+) metabolism-based immunoregulation and therapeutic potential |
title_full | NAD(+) metabolism-based immunoregulation and therapeutic potential |
title_fullStr | NAD(+) metabolism-based immunoregulation and therapeutic potential |
title_full_unstemmed | NAD(+) metabolism-based immunoregulation and therapeutic potential |
title_short | NAD(+) metabolism-based immunoregulation and therapeutic potential |
title_sort | nad(+) metabolism-based immunoregulation and therapeutic potential |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171153/ https://www.ncbi.nlm.nih.gov/pubmed/37165408 http://dx.doi.org/10.1186/s13578-023-01031-5 |
work_keys_str_mv | AT fangjiankai nadmetabolismbasedimmunoregulationandtherapeuticpotential AT chenwangwang nadmetabolismbasedimmunoregulationandtherapeuticpotential AT houpengbo nadmetabolismbasedimmunoregulationandtherapeuticpotential AT liuzhanhong nadmetabolismbasedimmunoregulationandtherapeuticpotential AT zuomuqiu nadmetabolismbasedimmunoregulationandtherapeuticpotential AT liushisong nadmetabolismbasedimmunoregulationandtherapeuticpotential AT fengchao nadmetabolismbasedimmunoregulationandtherapeuticpotential AT hanyuyi nadmetabolismbasedimmunoregulationandtherapeuticpotential AT lipeishan nadmetabolismbasedimmunoregulationandtherapeuticpotential AT shiyufang nadmetabolismbasedimmunoregulationandtherapeuticpotential AT shaochangshun nadmetabolismbasedimmunoregulationandtherapeuticpotential |